ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients"
Episode Synopsis
Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024.
In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in the Division of Gynecologic Oncology at the European Institute of Oncology, Milan, Italy, after he reported his group’s findings. “Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial,” Peccatori noted.
In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in the Division of Gynecologic Oncology at the European Institute of Oncology, Milan, Italy, after he reported his group’s findings. “Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial,” Peccatori noted.
In God we trust